Top

Journal of Cancer Research and Clinical Oncology

Published in:

01-06-2019 | Myocarditis | Review – Clinical Oncology

Immune checkpoint inhibitor therapy and myocarditis: a systematic review of reported cases

Authors: Suheil Albert Atallah-Yunes, Anis John Kadado, Gregory P. Kaufman, Jaime Hernandez-Montfort

Published in: Journal of Cancer Research and Clinical Oncology | Issue 6/2019

Abstract

Introduction

The advent of immune checkpoint inhibitors in the treatment of certain types of cancers has revolutionized cancer therapy. In general, these novel agents are more tolerable and have better safety profiles than conventional chemotherapy agents. Although a low incidence of myocarditis was noted as a side effect of immune checkpoint inhibitors in clinical trials, it is being increasingly cited in the literature as their use also increases.

Methods

Using a combination of search terms in the PubMed/Medline database and manual searches on Google Scholar and the bibliographies of articles identified, we reviewed all cases reported in the English language citing myocarditis associated with either pembrolizumab, nivolumab, ipilimumab, or any combination of these agents.

Results

A total of 42 cases were included in the study. Mean age was 65.5 years; 64% were male, 36% were female. One or two doses preceded the onset of myocarditis in 33% and 29% of cases, respectively. Steroids were used as the first-line therapy in 90% of cases. Complete heart block occurred in 36% of cases. Fourteen (33%) deaths were reported, with 64% and 29% of deaths occurring after one or two doses, respectively.

Conclusion

Most cases and fatalities of myocarditis occurred shortly after initiation of immune checkpoint inhibitor therapy. Arrhythmias, particularly complete heart block, appear to be related to the occurrence of more severe and fatal cases. The use of serial electrocardiograms or biomarkers of myocardial injury may be crucial in detecting early stages of the disease process. Further research establishing more specific guidelines is necessary in dealing with this potentially fatal side effect.

Arangalage D, Delyon J, Lermuzeaux M, Ekpe K, Ederhy S, Pages C, Lebbe C (2017) Survival after fulminant myocarditis induced by immune-checkpoint inhibitors. Ann Intern Med 167:683–684. https://doi.org/10.7326/L17-0396 CrossRefPubMed

Baldetti L, Melillo F, Beneduce A, Camici PG (2018) Combined checkpoint inhibitor-associated myocarditis and pulmonary vasculitis mimicking acute pulmonary embolism. Eur Heart J Cardiovasc Imaging. https://doi.org/10.1093/ehjci/jey191 CrossRef

Behling J, Kaes J, Munzel T, Grabbe S, Loquai C (2017) New-onset third-degree atrioventricular block because of autoimmune-induced myositis under treatment with anti-programmed cell death-1 (nivolumab) for metastatic melanoma. Melanoma Res 27:155–158. https://doi.org/10.1097/cmr.0000000000000314 CrossRefPubMed

Berg DD, Vaduganathan M, Nohria A, Davids MS, Alyea EP, Torre M, Padera RF Jr (2017) Immune-related fulminant myocarditis in a patient receiving ipilimumab therapy for relapsed chronic myelomonocytic leukaemia. Eur J Heart Fail 19:682–685. https://doi.org/10.1002/ejhf.806 CrossRefPubMed

Blauwet LA, Cooper LT (2010) Myocarditis. Prog Cardiovasc Dis 52:274–288. https://doi.org/10.1016/j.pcad.2009.11.006 CrossRefPubMedPubMedCentral

Bracamonte-Baran W, Cihakova D (2017) Cardiac autoimmunity: myocarditis. Adv Exp Med Biol 1003:187–221. https://doi.org/10.1007/978-3-319-57613-8_10 CrossRefPubMedPubMedCentral

Brahmer JR, Lacchetti C, Thompson JA (2018) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: american Society of Clinical Oncology Clinical Practice Guideline Summary. J Oncol Pract 14:247–249. https://doi.org/10.1200/JOP.18.00005 CrossRefPubMed

Caforio AL et al (2007) A prospective study of biopsy-proven myocarditis: prognostic relevance of clinical and aetiopathogenetic features at diagnosis. Eur Heart J 28:1326–1333. https://doi.org/10.1093/eurheartj/ehm076 CrossRefPubMed

Caforio ALP, Malipiero G, Marcolongo R, Iliceto S (2017) Myocarditis: a clinical overview. Curr Cardiol Rep 19:63. https://doi.org/10.1007/s11886-017-0870-x CrossRefPubMed

Chen Q, Huang DS, Zhang LW, Li YQ, Wang HW, Liu HB (2018) Fatal myocarditis and rhabdomyolysis induced by nivolumab during the treatment of type B3 thymoma. Clin Toxicol (Phila) 56:667–671. https://doi.org/10.1080/15563650.2017.1401079 CrossRef

Collin M (2016) Immune checkpoint inhibitors: a patent review (2010-2015). Expert Opin Ther Pat 26:555–564. https://doi.org/10.1080/13543776.2016.1176150 CrossRefPubMed

Cooper LT et al (2007) The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology. J Am Coll Cardiol 50:1914–1931. https://doi.org/10.1016/j.jacc.2007.09.008 CrossRefPubMed

Copeland-Halperin R, Sahni GD (2018) Autoimmune Myocarditis With AV Block: Too Much of a Good Thing? JACC

Cristina AADLA, Escudier-Villa JM, Ortega Marcos J, Silva-Melchor L (2017) Progressive exertional dyspnea and fatigue in an oncology-patient. Austin J Clin Cardiolog 4(2):1058

Curtis JR et al (2007) Heart failure among younger rheumatoid arthritis and Crohn’s patients exposed to TNF-alpha antagonists. Rheumatology (Oxford) 46:1688–1693. https://doi.org/10.1093/rheumatology/kem212 CrossRef

Escudier M et al (2017) Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity. Circulation 136:2085–2087. https://doi.org/10.1161/CIRCULATIONAHA.117.030571 CrossRefPubMed

Farhad H et al (2016) Characterization of the changes in cardiac structure and function in mice treated with anthracyclines using serial cardiac magnetic resonance imaging. Circ Cardiovasc Imaging 9:15. https://doi.org/10.1161/circimaging.115.003584 CrossRef

Felker GM, Boehmer JP, Hruban RH, Hutchins GM, Kasper EK, Baughman KL, Hare JM (2000) Echocardiographic findings in fulminant and acute myocarditis. J Am Coll Cardiol 36:227–232CrossRefPubMed

Frigeri M et al (2018) Immune checkpoint inhibitor-associated myocarditis: a new challenge for cardiologists. Can J Cardiol 34:92 e91–92 e93. https://doi.org/10.1016/j.cjca.2017.09.025 CrossRef

Fukasawa Y et al (2017) Nivolumab-induced myocarditis concomitant with myasthenia gravis. Case Rep Oncol 10:809–812. https://doi.org/10.1159/000479958 CrossRefPubMedPubMedCentral

Fung G, Luo H, Qiu Y, Yang D, McManus B (2016) Myocarditis. Circ Res 118:496–514. https://doi.org/10.1161/CIRCRESAHA.115.306573 CrossRefPubMed

Gallegos C, Rottmann D, Nguyen VQ, Baldassarre LA (2019) Myocarditis with checkpoint inhibitor immunotherapy: case report of late gadolinium enhancement on cardiac magnetic resonance with pathology correlate. Eur Heart J Case Rep. https://doi.org/10.1093/ehjcr/yty149 CrossRefPubMedPubMedCentral

Ganatra S, Neilan TG (2018) Immune checkpoint inhibitor-associated myocarditis. Oncologist 23:879–886. https://doi.org/10.1634/theoncologist.2018-0130 CrossRefPubMedPubMedCentral

Geisler BP, Raad RA, Esaian D, Sharon E, Schwartz DR (2015) Apical ballooning and cardiomyopathy in a melanoma patient treated with ipilimumab: a case of takotsubo-like syndrome. J Immunother Cancer 3:4. https://doi.org/10.1186/s40425-015-0048-2 CrossRefPubMedPubMedCentral

Gibson R, Delaune J, Szady A, Markham M (2016) Suspected autoimmune myocarditis and cardiac conduction abnormalities with nivolumab therapy for non-small cell lung cancer. BMJ Case Rep. https://doi.org/10.1136/bcr-2016-216228 CrossRefPubMedPubMedCentral

Guglin M, Nallamshetty L (2012) Myocarditis: diagnosis and treatment. Curr Treat Options Cardiovasc Med 14:637–651. https://doi.org/10.1007/s11936-012-0204-7 CrossRefPubMed

Hargadon KM, Johnson CE, Williams CJ (2018) Immune checkpoint blockade therapy for cancer: an overview of FDA-approved immune checkpoint inhibitors. Int Immunopharmacol 62:29–39. https://doi.org/10.1016/j.intimp.2018.06.001 CrossRefPubMed

Hauck AJ, Kearney DL, Edwards WD (1989) Evaluation of postmortem endomyocardial biopsy specimens from 38 patients with lymphocytic myocarditis: implications for role of sampling error. Mayo Clin Proc 64:1235–1245CrossRefPubMed

Heinzerling L et al (2016) Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy. J Immunother Cancer 4:50. https://doi.org/10.1186/s40425-016-0152-y CrossRefPubMedPubMedCentral

Imai R, Ono M, Nishimura N, Suzuki K, Komiyama N, Tamura T (2018) Fulminant myocarditis caused by an immune checkpoint inhibitor: a case report with pathological findings. J Thorac Oncol 15:15. https://doi.org/10.1016/j.jtho.2018.10.156 CrossRef

Inayat F, Masab M, Gupta S, Ullah W (2018) New drugs and new toxicities: pembrolizumab-induced myocarditis. BMJ Case Rep. https://doi.org/10.1136/bcr-2017-223252 CrossRefPubMed

Jain V, Mohebtash M, Rodrigo ME, Ruiz G, Atkins MB, Barac A (2018) Autoimmune myocarditis caused by immune checkpoint inhibitors treated with antithymocyte globulin. J Immunother 41:332–335. https://doi.org/10.1097/CJI.0000000000000239 CrossRefPubMed

Janardhanan R (2016) Myocarditis with very high troponins: risk stratification by cardiac magnetic resonance. J Thorac Dis 8:E1333–E1336. https://doi.org/10.21037/jtd.2016.10.60 CrossRefPubMedPubMedCentral

Johnson DB et al (2016) Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med 375:1749–1755. https://doi.org/10.1056/NEJMoa1609214 CrossRefPubMedPubMedCentral

Katsume Y, Isawa T, Toi Y, Fukuda R, Kondo Y, Sugawara S, Ootomo T (2018) Complete atrioventricular block associated with pembrolizumab-induced acute myocarditis: the need for close cardiac monitoring. Intern Med 57:3157–3162. https://doi.org/10.2169/internalmedicine.0255-17 CrossRefPubMedPubMedCentral

Kindermann I et al (2012) Update on myocarditis. J Am Coll Cardiol 59:779–792. https://doi.org/10.1016/j.jacc.2011.09.074 CrossRefPubMed

Kobashigawa JA et al (2006) Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report. Am J Transpl 6:1377–1386. https://doi.org/10.1111/j.1600-6143.2006.01290.x CrossRef

Kobashigawa J et al (2011) Report from a consensus conference on antibody-mediated rejection in heart transplantation. J Heart Lung Transpl 30:252–269. https://doi.org/10.1016/j.healun.2010.11.003 CrossRef

Laubli H, Balmelli C, Bossard M, Pfister O, Glatz K, Zippelius A (2015) Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma. J Immunother Cancer 3:11. https://doi.org/10.1186/s40425-015-0057-1 CrossRefPubMedPubMedCentral

Lauer B, Niederau C, Kuhl U, Schannwell M, Pauschinger M, Strauer BE, Schultheiss HP (1997) Cardiac troponin T in patients with clinically suspected myocarditis. J Am Coll Cardiol 30:1354–1359CrossRefPubMed

Lopez EM, Dunn S, Mazimba S (2018) Malignant arrhythmias in autoimmune myocarditis secondary to immune checkpoint blockade treatment. J Am College Cardiol 71:A2375. https://doi.org/10.1016/S0735-1097(18)32916-4 CrossRef

Love VA, Grabie N, Duramad P, Stavrakis G, Sharpe A, Lichtman A (2007) CTLA-4 ablation and interleukin-12 driven differentiation synergistically augment cardiac pathogenicity of cytotoxic T lymphocytes. Circ Res 101:248–257. https://doi.org/10.1161/circresaha.106.147124 CrossRefPubMed

Mahmood SS et al (2018) Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol 71:1755–1764. https://doi.org/10.1016/j.jacc.2018.02.037 CrossRefPubMedPubMedCentral

Mahrholdt H et al (2004) Cardiovascular magnetic resonance assessment of human myocarditis: a comparison to histology and molecular pathology. Circulation 109:1250–1258. https://doi.org/10.1161/01.CIR.0000118493.13323.81 CrossRefPubMed

Martinez-Calle N et al (2018) Anti-PD1 associated fulminant myocarditis after a single pembrolizumab dose: the role of occult pre-existing autoimmunity. Haematologica 103:318–321. https://doi.org/10.3324/haematol.2017.185777 CrossRef

Matson DR, Accola MA, Rehrauer WM, Corliss RF (2018) Fatal myocarditis following treatment with the PD-1 inhibitor nivolumab. J Forensic Sci 63:954–957. https://doi.org/10.1111/1556-4029.13633 CrossRefPubMed

Mehta A, Gupta A, Hannallah F, Koshy T, Reimold S (2016) Myocarditis as an immune-related adverse event with ipilimumab/nivolumab combination therapy for metastatic melanoma. Melanoma Res 26:319–320. https://doi.org/10.1097/CMR.0000000000000251 CrossRefPubMed

Monge C et al (2018) Myocarditis in a patient treated with Nivolumab and PROSTVAC: a case report. J Immunother Cancer 6:150. https://doi.org/10.1186/s40425-018-0473-0 CrossRefPubMedPubMedCentral

Moslehi JJ, Salem JE, Sosman JA, Lebrun-Vignes B, Johnson DB (2018) Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet 391:933. https://doi.org/10.1016/S0140-6736(18)30533-6 CrossRefPubMedPubMedCentral

Nasr F, El Rassy E, Maalouf G, Azar C, Haddad F, Helou J, Robert C (2018) Severe ophthalmoplegia and myocarditis following the administration of pembrolizumab. Eur J Cancer 91:171–173. https://doi.org/10.1016/j.ejca.2017.11.026 CrossRefPubMed

Nieminen MS, Heikkila J, Karjalainen J (1984) Echocardiography in acute infectious myocarditis: relation to clinical and electrocardiographic findings. Am J Cardiol 53:1331–1337CrossRefPubMed

Norwood TG et al (2017) Smoldering myocarditis following immune checkpoint blockade. J Immunother Cancer 5:91. https://doi.org/10.1186/s40425-017-0296-4 CrossRefPubMedPubMedCentral

Okazaki T et al (2003) Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. Nat Med 9:1477–1483. https://doi.org/10.1038/nm955 CrossRefPubMed

Reuben A et al (2017) Comparative immunologic characterization of autoimmune giant cell myocarditis with ipilimumab. Oncoimmunology 6:e1361097. https://doi.org/10.1080/2162402X.2017.1361097 CrossRefPubMedPubMedCentral

Rodriguez ER, Skojec DV, Tan CD, Zachary AA, Kasper EK, Conte JV, Baldwin WM 3rd (2005) Antibody-mediated rejection in human cardiac allografts: evaluation of immunoglobulins and complement activation products C4d and C3d as markers. Am J Transpl 5:2778–2785. https://doi.org/10.1111/j.1600-6143.2005.01074.x CrossRef

Rota E et al (2019) Concomitant myasthenia gravis, myositis, myocarditis and polyneuropathy, induced by immune-checkpoint inhibitors: a life-threatening continuum of neuromuscular and cardiac toxicity. eNeurological Sci 14:4–5. https://doi.org/10.1016/j.ensci.2018.11.023 CrossRef

Sakai T, Sasada S, Jyo C, Ishioka K, Takahashi S, Nakamura M (2017) Acute myocarditis and pericarditis after nivolumab treatment in patients with non-small cell lung cancer. Ann Oncol 28:mdx697.072–mdx697.072. https://doi.org/10.1093/annonc/mdx697.072 CrossRef

Samara Y, Yu CL, Dasanu CA (2018) Acute autoimmune myocarditis and hepatitis due to ipilimumab monotherapy for malignant melanoma. J Oncol Pharm Pract 15:1078155218755868. https://doi.org/10.1177/1078155218755868 CrossRef

Semper H, Muehlberg F, Schulz-Menger J, Allewelt M, Grohe C (2016) Drug-induced myocarditis after nivolumab treatment in a patient with PDL1- negative squamous cell carcinoma of the lung. Lung Cancer 99:117–119. https://doi.org/10.1016/j.lungcan.2016.06.025 CrossRefPubMed

Simsek M, Tekin SB, Bilici M (2019) Immunological agents used in cancer treatment. Eurasian J Med 51:90–94. https://doi.org/10.5152/eurasianjmed.2018.18194 CrossRefPubMed

Tadokoro T, Keshino E, Mohri M (2016) A case of acute myocarditis during treatment with anti-PD-1 antibody nivolumab in a melanoma patient. J Cardiac Fail 22:220. https://doi.org/10.1016/j.cardfail.2016.07.355 CrossRef

Tajmir-Riahi A, Bergmann T, Schmid M, Agaimy A, Schuler G, Heinzerling L (2018) Life-threatening autoimmune cardiomyopathy reproducibly induced in a patient by checkpoint inhibitor therapy. J Immunother 41:35–38. https://doi.org/10.1097/CJI.0000000000000190 CrossRefPubMed

Tarrio ML, Grabie N, Bu DX, Sharpe AH, Lichtman AH (2012) PD-1 protects against inflammation and myocyte damage in T cell-mediated myocarditis. J Immunol 188:4876–4884. https://doi.org/10.4049/jimmunol.1200389 CrossRefPubMedPubMedCentral

Tay RY, Blackley E, McLean C, Moore M, Bergin P, Gill S, Haydon A (2017) Successful use of equine anti-thymocyte globulin (ATGAM) for fulminant myocarditis secondary to nivolumab therapy. Br J Cancer 117:921–924. https://doi.org/10.1038/bjc.2017.253 CrossRefPubMedPubMedCentral

Thibault C, Vano Y, Soulat G, Mirabel M (2018) Immune checkpoint inhibitors myocarditis: not all cases are clinically patent. Eur Heart J 39:3553. https://doi.org/10.1093/eurheartj/ehy485 CrossRefPubMed

Varricchi G et al (2017) Cardiotoxicity of immune checkpoint inhibitors ESMO Open 2:e000247. https://doi.org/10.1136/esmoopen-2017-000247 CrossRefPubMed

Weber JS (2012) Practical management of immune-related adverse events from immune checkpoint protein antibodies for the oncologist. Am Soc Clin Oncol Educ 15:174–177. https://doi.org/10.14694/edbook_am.2012.32.174 CrossRef

Yamaguchi S et al (2018) Late-onset fulminant myocarditis with immune checkpoint inhibitor nivolumab. Can J Cardiol 34:812.e811–812.e813. https://doi.org/10.1016/j.cjca.2018.03.007 CrossRef

Title: Immune checkpoint inhibitor therapy and myocarditis: a systematic review of reported cases
Authors: Suheil Albert Atallah-Yunes
Anis John Kadado
Gregory P. Kaufman
Jaime Hernandez-Montfort
Publication date: 01-06-2019
Publisher: Springer Berlin Heidelberg
Keywords: Myocarditis
Checkpoint Inhibitors
Published in: Journal of Cancer Research and Clinical Oncology / Issue 6/2019
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-019-02927-x

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Introduction

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 6/2019

Focal adhesion kinase (FAK) phosphorylation is a key regulator of embryonal rhabdomyosarcoma (ERMS) cell viability and migration

Twice- vs. thrice-weekly moderate hypofractionated radiotherapy for prostate cancer: does overall treatment time matter?

Clinical impact of PD-L1 and PD-1 expression in squamous cell cancer of the vulva

Alternative and canonical NF-kB pathways DNA-binding hierarchies networks define Hodgkin lymphoma and Non-Hodgkin diffuse large B Cell lymphoma respectively

First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression

Patient-reported outcomes in the phase 3 BFORE trial of bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials